Radioactive beta-endorphin accumulated specifically in the lung and liver — not other tissues — suggesting these organs have dedicated beta-endorphin receptors.
Lung and liver specificBeta-endorphin binding sites distinct from classical mu/delta/kappa receptors
What the researchers found
Radioactive beta-endorphin injected intravenously accumulated specifically in the lung and liver but not other tissues. Four lines of evidence confirmed this was specific receptor binding, not passive trapping.
First, adding excess unlabeled beta-endorphin reduced the labeled peptide in lung and liver.
Second, injecting unlabeled beta-endorphin via the femoral vein (which passes through the lungs first) rapidly increased blood levels of the pre-injected labeled peptide, displacing it from lung binding sites. Injection via the carotid artery (bypassing the lungs) did not have this effect.
Third, immunoreactive labeled peptide that had lost its receptor-binding ability did not accumulate in lung or liver.
Fourth, dynorphin (1-13) and ethylketocyclazocine (kappa agonist) displaced beta-endorphin from these sites, but DADLE (delta agonist) and naloxone (mu antagonist) did not. This pharmacological profile indicates kappa-type binding sites.
Why it matters
The lung and liver as beta-endorphin binding sites was unexpected. These organs may serve as a peripheral opioid reservoir or clearance system. Lung kappa receptors could be involved in respiratory regulation and pain modulation.
How the study worked
Radiolabeled [125I-Tyr27]beta-endorphin injected intravenously into rats. Tissue-to-serum ratios measured. Displacement studies with selective opioid agonists and antagonists. HPLC-purified immunoreactive control peptide tested. Routes of injection varied to isolate lung-specific binding.
What this study cannot tell us
Tested in rats, not people. Radiolabeled peptide studies have technical artifacts. The functional significance of lung and liver binding was not determined. Only one time point (15 minutes) was studied.
How to read the evidence
Preliminary animal study with four lines of evidence but function of binding sites unknown.
When this study was published
Published in 1988 — early evidence for non-classical peripheral opioid binding sites.
The bigger picture
Non-classical opioid binding sites in the lung and liver could explain some systemic effects of endorphins beyond pain and mood — potentially affecting breathing regulation and metabolism.
Questions still open
- What is the function of lung beta-endorphin receptors?
- Do these non-classical receptors play a role in liver disease or respiratory regulation?
Common questions
Why would the lung have endorphin receptors?
Are these the same as brain opioid receptors?
Read the original research
In vivo evidence for the specific binding of human beta-endorphin to the lung and liver of the rat.
Biochemical pharmacology, 37(11), 2273-8
Citation
Sato, H; Sugiyama, Y; Sawada, Y; Iga, T; Hanano, M. (1988). In vivo evidence for the specific binding of human beta-endorphin to the lung and liver of the rat.. Biochemical pharmacology, 37(11), 2273-8.